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Abstract                                                                                    
The aim of the present study was to compare concentrations of IgG, IgA, IgM and IgD 
in both serum and saliva samples from smoking and non-smoking subjects using a 
protein microarray assay.  The findings were also compared to previous studies.  Serum 
and saliva were collected from 48 smoking male subjects and 48 age-matched never-
smoker male subjects.  The protein microarray assays for detection of human IgG, IgM, 
IgA and IgD were established and optimized using Ig class-specific affinity purified 
goat anti-human Ig-Fc capture antibodies and horseradish peroxidase (HRP)-
conjugated goat anti-human Ig-Fc detection antibodies.  The Ig class specificity of the 
microarray assays was verified and the optimal dilutions of serum and saliva samples 
was determined for quantification of Ig levels against standard curves.  We found that 
smoking is associated with reduced IgG concentrations and enhanced IgA 
concentrations in both serum and saliva.  By contrast, smoking differentially affected 
IgM concentrations – causing increased concentrations in serum, but decreased 
concentrations in saliva.  Smoking was associated with decreased IgD concentrations 
in serum, and did not have a significant effect on the very low IgD concentrations in 
saliva.  Thus, cigarette smoking differentially affects the levels of Ig classes 
systemically and in the oral mucosa.  Although there is variation between the results of 
different published studies, there is a consensus that smokers have significantly reduced 
levels of IgG in both serum and saliva.  A functional antibody deficiency associated 
with smoking may compromise the body’s response to infection and result in a 
predisposition to the development of autoimmunity.  
 
Keywords: cigarette smoke; immunoglobulin; IgG; IgA; IgM; IgD; serum; saliva; 
protein microarray. 
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Introduction 
Cigarette smoke (CS) has numerous toxic chemical constituents, which have cytotoxic, 
mutagenic, carcinogenic, and/or antigenic properties (1, 2).  The immune system is 
affected in a variety of ways by CS, ranging from immunosuppression and increased 
susceptibility to infection to promotion of inflammation and immunopathology (3).  
With regard to the latter, CS is the major cause of chronic obstructive pulmonary 
disease (COPD) (4), and smoking is a recognised risk factor for the occurrence of 
autoimmune diseases (5). 
 An important facet of these effects is that CS causes dysregulation and 
impairment of B lymphocytes (6-10); nicotinic receptors are expressed by B cells (11), 
and long-term exposure to nicotine can suppress B cell development, proliferation and 
immune functions (9, 12-14).  Numerous studies have investigated the effects of 
tobacco smoking on immunoglobulin (Ig) levels using a variety of assays.  In serum 
samples from smokers and non-smokers, Igs have been quantified by ELISA (15), 
immunodiffusion assay (16), nephelometry (17-19), radioimmunoassay (20) and 
turbidimetry (21, 22).  Investigations of Ig levels in the saliva of smokers and non-
smokers have been carried out using mainly ELISA (23-29), although immunodiffusion 
assays (30-32) or turbidimetry (33) have also been used.  These studies have generated 
varying results concerning the effects of smoking on the concentrations of different Ig 
classes (IgG, IgA, IgM) in serum or saliva, reporting that smoking is associated with 
increased, decreased or unchanged Ig class concentrations compared to non-smoking 
controls.  However, these studies have not investigated simultaneously the effects of 
smoking on Ig class concentrations in both serum and saliva in the same subjects.  In 
addition, few of these studies have investigated the effects of smoking on levels of IgD 
(20, 22): this is expressed particularly in the upper aerodigestive tract in humans (34), 
which is heavily exposed to CS in smokers. 
 The aim of the present study was therefore the compare concentrations of IgD, 
as well as IgG, IgA and IgM, in both serum and saliva samples from smoking and 
non-smoking subjects.  Furthermore, this was undertaken using a protein microarray 
assay to quantify the Ig class levels – this relatively recent technique was not used in 
any of the previous studies referred to above (15-33).  The protein microarray used 
was essentially a miniaturised version of a sandwich/capture ELISA.  However, in 
comparison to ELISAs, microarrays require smaller sample volumes, are more 
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sensitive and have a greater dynamic range. These factors make microarrays a cheaper 
and potentially more sensitive alternative to ELISAs for the large-scale detection of 
known proteins, including Igs (35). 
 
Materials and Methods 
The study was conducted in accordance with the Basic & Clinical Pharmacology & 
Toxicology policy for experimental and clinical studies (36). 
 
Subjects. Serum and saliva were collected from 48 smoking male subjects (median age 
= 30 years; age range 19-51) and 48 age-matched never-smoker male subjects (median 
age = 32.5 years; age range 20-56), all of whom were blood bank volunteers at King 
Abdulaziz Hospital, Jeddah, Saudi Arabia.  As healthy blood bank volunteer donors at 
the time of sample collection, all the subjects fulfilled the following criteria:   No history 
or evidence of significant illness/disease, including lung/respiratory tract, heart/chest, 
liver, kidney, nervous system, diabetes, cancer.  No infectious diseases or recent 
vaccinations, fever, flu-like illness, sore throat or antibiotic treatment.  No recent dental 
extractions.  No recent surgery, blood transfusion or organ transplantation.  No recent 
anaemia, high blood pressure or abnormal pulse.  
 The serum and saliva samples were aliquoted and stored at -20oC. They were 
transported on ice to Queen’s Medical Centre, Nottingham, UK, and then stored frozen 
until assayed. Ethical approval was granted by The Biomedical Research Ethics 
Committee, Ministry of Higher Education, King Abdulaziz University, Faculty of 
Medicine.  The smoking subjects smoked a median of 20 cigarettes/day (range 1-40), 
and had smoked for a median of 10 years (range 2-33). 
 Donors ceased from eating and drinking (and smoking) about 1 hour prior to 
donation. Smoker and non-smoker donors were requested to provide 10 ml of blood 
and 5 ml of unstimulated saliva after signing an informed-consent form. Blood samples 
were collected in plain serum separation tubes (BD Vacutainer™ Venous Blood 
Collection Tubes: SST™ Serum Separation Tubes: Hemogard). The tubes were 
centrifuged at 2000g for 10 minutes. Saliva was collected over a period of 5-10 minutes. 
After cleaning the mouth with mouthwash and rinsing with water over 5 min, donors 
provided saliva into plain separation tubes (Thermo Fisher Scientific) and the tubes 
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kept on ice. Then, the saliva samples were centrifuged at 2600g for 15 minutes at 4°C. 
Samples were aliquoted and immediately frozen at −20°C.  
 
Human Ig class microarrays. Affinity purified goat anti-human Ig-Fc capture 
antibodies and horseradish peroxidase (HRP)-conjugated goat anti-human Ig-Fc 
detection antibodies provided in the Bethyl Laboratories Human IgG/IgA/IgM/IgD 
ELISA Quantitation Sets (obtained from Cambridge Bioscience) were used to 
established the microarray assay for quantifying human IgG, IgA, IgM and IgD, 
respectively. As accurate quantification of each Ig class requires the capture and 
detection antibodies to be highly specific for the relevant class, this was initially 
confirmed by running the Ig class-specific ELISAs according to the manufacturer’s 
instructions and demonstrating that each capture/detection antibody pair bound only the 
relevant class of purified Ig (obtained from Athenas Research Technology); for 
example, the anti-IgG-Fc capture and detection antibodies detected human IgG, but not 
IgA, IgM or IgD (Figure 1).   
 To transpose the assay to the microarray platform, optimisation studies were 
undertaken to determine the optimal printing buffer, blocking buffer, and 
concentrations of each capture antibody and detection antibody.  The optimised 
microarray assays for detection of human IgG, IgA, IgM and IgD were then performed 
as follows: 
 Capture antibody goat anti-human Ig-Fc (100μg/ml in PBS-Trehalose 
(50mM)) was loaded onto a 384 well plate (Genetix), and printed in double 
quadriplicate in a 16 x16 array format onto a poly-l-lysine-coated glass slide 
(Thermofisher, UK) using a Biorobotics Microgrid II arrayer (Microgrid) and a 
silicon contact pin (Parallel Synthesis Technologies, USA). During printing, the array 
chamber was set to 200C and 60% humidity, and the spot diameter was 315μm. Slides 
were held under a vacuum overnight. On the next day, the slides were blocked with 
BSA blocking buffer with shaking for 1 h at room temperature. After incubation, the 
slides were washed 3 times with PBS containing 0.05 % Tween-20 on the shaker for 3 
min each wash. Ig standards, serum and saliva samples were added and incubated for 
1 h. Following incubation, the slides were washed as described above. Then, 100 l of 
the HRP-conjugated detection antibody was added and the slides were incubated for 1 
h at room temperature on a shaker.  The slides were washed, as described above, and 
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100 l biotinylated-tyramide amplification reagent was applied to the slides and 
incubated for 10 min at room temperature. After the incubation, the slides were 
washed as described above, and 100 l Cy5-conjugated streptavidin (1:1000 in 3 % 
BSA) was applied to each block. The slides were incubated for 15 min on the shaker 
in the dark. Finally, the slides were released from the holder, washed in ultra-pure 
water for 5 min, and centrifuged for 3 min. After processing, slides were immediately 
scanned in a GenePix 4200AL microarray scanner, to measure the fluorescence (Cy5 
Fluor 635).  
 The microarray assays had intra-assay coefficient of variation (CV) <10%, and 
inter-assay CV <15%.  The Ig class specificity demonstrated in the ELISA format was 
maintained in the microarray assays, as exemplified for detection of IgG (Figure 2). 
 
Statistical Analysis.  The data were not normally distributed and therefore comparisons 
between groups were made using the Kruskal-Wallis test for non-paired data. Statistical 
analyses were performed using GraphPad Prism 7. 
 
Results 
Determining optimal sample dilutions for Ig class quantification. 
The microarray assays for detection of human IgG, IgM, IgA and IgD were established 
and optimized as described in the Material & Methods section.  Experiments were 
undertaken to determine the optimal dilutions of human serum for accurate 
quantification of each Ig class.  As shown in figure 3, the serum dilutions that generated 
signals corresponding to the sensitive regions of the standard curves were 1:40,000 for 
IgG and IgA, and 1:200 for IgM and IgD.  A saliva dilution of 1:2 was suitable for 
detection of salivary Igs (data not shown). 
 
Serum Ig class concentrations in smokers and non-smokers. 
The serum Ig concentrations for the smokers and non-smokers are shown in figure 4a-
d.  The IgG levels in smokers were very significantly lower than those in non-smokers 
(p<0.0001; figure 4a); conversely, the serum IgM levels were very significantly higher 
in smokers than non-smokers (p<0.0001; figure 4b).   The serum IgA levels were also 
significantly higher in smokers (p<0.05; figure 4c), but the smokers’ IgD 
concentrations were significantly lower than in the non-smokers (p<0.05; figure 4d). 
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Salivary Ig class concentrations in smokers and non-smokers. 
Figure 4e-h shows that, as in serum, IgG concentrations in the saliva of smokers were 
significantly lower than in non-smokers (p<0.05; figure 4e), and salivary IgA 
concentrations were significantly higher in smokers (p<0.05; figure 4g).  By contrast, 
IgM levels were very significantly lower in the saliva of the smokers compared to the 
non-smokers (p<0.0001, figure 4f), which is the opposite of the findings for the serum 
levels of IgM described above (figure 4b).  There was no significant difference in the 
very low concentrations of salivary IgD between smokers and non-smokers (figure 4h). 
 There were no statistically significant correlations between serum and salivary 
Ig levels in the same subjects (either smokers or non-smokers) for any of the four Ig 
classes measured (data not shown). Also, there were no significant correlations between 
smoking pack-years and Ig class levels in either serum or saliva samples. 
 
 
Discussion 
Our findings indicate that smoking is associated with reduced IgG concentrations in 
both serum and saliva, and enhanced IgA concentrations in both serum and saliva.  By 
contrast, smoking differentially affected IgM concentrations – causing increased 
concentrations in serum, but decreased concentrations in saliva.  We found smoking to 
be associated with decreased IgD concentrations in serum, and not to have a significant 
effect on the very low IgD concentrations in saliva. 
 Tables 1 and 2 summarize the findings in the present study, together with the 
results reported in previous studies (quoted in the Introduction) that investigated the 
effects of smoking on levels of IgG, IgM, IgA and IgD in serum (Table 1) or in saliva 
(Table 2).  As mentioned in the Introduction, unlike the present study, these previous 
studies did not investigate Ig concentrations in both serum and saliva; few determined 
IgD concentrations (two for serum and none for saliva); and none used microarray 
technology.  The advantages of the microarray platform include its sensitivity and broad 
dynamic range (0 to 65,000 fluorescence units, compared to the 0 to 4 optical density 
units in ELISA), and the increased number of replicates that can readily be performed 
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within an assay together with detailed feature analysis enabling poorly-performing 
replicates to be legitimately excluded, hence reducing replicate variation. 
 Considering all the studies summarized in Tables 1 and 2 that investigated the 
effects of smoking on IgG levels, 6/7 (including the present study) reported a significant 
decrease in IgG concentrations in the serum of smokers; also 2/3 studies (including the 
present study) reported a significant reduction in IgG levels in the saliva of smokers. 
Thus, there is a strong consensus of evidence that smoking is associated with reduced 
IgG levels both systemically and in the oral mucosa.  It would be of interest to examine 
the effects of smoking on IgG subclasses, especially as these are known to be affected 
in COPD (37). 
 By contrast, there is no clear consensus for the effects of smoking on IgA levels, 
with different studies reporting an increase, a decrease, or no effect of smoking on IgA 
concentrations in either serum (Table 1) or saliva (Table 2).  The reason for this 
variation are unclear:  it does not appear to be related to different types of assays being 
used (e.g. nephelometry versus turbidimetry versus ELISA, etc.) since, for example, 
amongst the seven studies that used ELISA to determine salivary IgA levels, one 
reported an increase, three reported no change and three reported a decrease in smokers 
compared to non-smokers.  Other possible factors leading to the variations could 
include ethnicity, amount of smoking and relative detection of IgA1 versus IgA2. 
 Five studies listed in Table 1 reported no significant effects of smoking on 
serum levels of IgM, whereas a very significant increase in smokers was observed in 
the present study.  This may be because, in the present study, several smokers had 
particularly high serum IgM concentrations, plus very little variation was found in the 
serum IgM levels of non-smokers (figure 4b).  On the other hand, the present study 
agrees with 2/3 other studies in finding reduced levels of IgM in the saliva of smokers 
compared to non-smokers.  Overall, the present study agrees with the consensus view 
of other studies that smoking has different effects on IgM levels in serum and saliva. 
 The concentrations of IgD are very low in serum and extremely low in saliva, 
with an insufficient number of studies for a consensus view on the effects of smoking 
to be drawn.  There is, therefore, clear scope for further studies of the effects of smoking 
on IgD levels in both serum and saliva.  The importance of IgD in the upper 
aerodigestive tract in humans is indicated by the high numbers of IgD-producing B cells 
in tonsils, adenoids, salivary and lachrymal glands, and nasal mucosa; whereas IgD 
producing B cells are much less frequent in peripheral lymph nodes, spleen, bone 
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marrow and intestinal mucosa (34).  Furthermore, IgD recognizes a range of pathogenic 
microbes often found in the upper aerodigestive tract of humans, consistent with a 
protective role for IgD in this location (34).  A better understanding of the effects of 
smoking on IgD is therefore important. 
 Although the effects of tobacco smoking on IgE levels were not the subject of 
the present study, this is clearly of importance, not least since smoking exacerbates 
allergic conditions.  Numerous previous studies have shown that tobacco smoking is 
associated with elevated levels of serum IgE (38-43); it would also be of interest to 
determine the effects of smoking on salivary IgE. 
 The lack of correlation between smoking pack years and Ig class levels in serum 
and saliva that we observed is broadly consistent with the findings of others.  One study 
reported a significant inverse correlation between salivary IgA concentrations and 
current level of smoking, but no correlation between smoking and salivary IgG or IgM 
concentrations (23).  By contrast, another study reported there to be no correlation 
between salivary IgA levels and frequency of duration of smoking (33).  With regard 
to serum Igs, no significant correlation was found between IgD levels and duration of 
smoking (20).  Another study reported a significant correlation between serum IgG 
concentrations and the number of cigarettes smoked per day; however, these authors 
also pointed out that there was a clearly significant difference in serum IgG levels 
between  non-smokers and those a relatively low number of cigarettes (≤10 per day) 
(17).  They also reported a low significance for the correlation between IgM 
concentrations and level of smoking, but no significance for the correlation of IgA 
levels and smoking (17).  Overall, our findings, and these previous studies, are 
consistent with the proposal that any level of cigarette smoking affects Ig levels in 
serum and saliva, with smoking per se being the main factor, regardless of whether the 
level of smoking is low, moderate or high.   
 A variety of mechanisms could be involved in the differential effects of smoking 
on the concentrations of Ig classes in serum and saliva:  these might include direct 
effects on B cells and indirect effects on T cells and antigen presenting cells, which 
could affect Ig class switching and/or differential survival of naïve B cells or memory 
B cells (3).  In this regard, we have preliminary evidence (see online Supporting 
Information) that the in vitro production of IgG, IgM and IgA by human peripheral 
blood mononuclear cells (PBMCs) or purified B cells stimulated with anti-CD40 plus 
IL-4 and pokeweed mitogen is inhibited by cigarette smoke extract or nicotine.  It is 
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interesting that pure nicotine appears to suppress Ig production to the same extent as 
CSE, suggesting that nicotine is an important contributor to the Ig-suppressive effect of 
whole CSE.  Furthermore, these observations are consistent with the investigations of 
Skok et al. in murine models into the effects of nicotinic acetylcholine receptors 
(nAChRs) expressed by immature and mature B cells (12-14).  They deduced that the 
activity of nAChR promotes the survival and development of immature B cells in the 
bone marrow, but suppresses B cell activation in response to antigenic challenge in 
secondary lymphoid tissues like the spleen (12, 13).  In this regard, wild-type mice 
(expressing nAChR) were found to produce higher levels of natural antibodies that 
nAChR-knockout mice, but wild-type mice produced lower levels of antigen-specific 
IgG antibodies than the nAChR-knockout mice when challenged (12).  This may help 
to explain our observation that smokers, compared to non-smokers, have very 
significantly lower levels of serum IgG (most of which is derived from antigen-
stimulated B cells), but very significantly higher levels of serum IgM (that may include 
a higher proportion of natural antibodies).  By contrast, different processes are likely to 
determine salivary Ig, where we found both IgG and IgM to be decreased in smokers.  
 It should also be noted, however, that the suppression by CSE and nicotine of 
IgA and IgM production by polyclonally-stimulated PBMCs and B cells (see online 
Supporting Information)  is in contrast to our findings that IgA levels were increased in 
the sera and saliva of smokers, as were the levels of IgM in smokers’ sera.  This suggests 
that the in vitro findings cannot fully explain the effects of CSE and nicotine in smokers 
in vivo, which are likely to be much more complex.  For example, the increased 
occurrence of infections in the upper respiratory tract of smokers (44) is likely to 
stimulate the production of IgA as a major mucosal Ig.  This complexity is also reflected 
in the effects of cigarette smoking on antibodies specific to particular antigens, as 
distinct from total Ig class levels.  For example, smokers were reported to have raised 
levels of anti-pneumococcal IgG antibodies, presumably due to an increased occurrence 
of pneumococcal infections of the respiratory tract (45).  By contrast, smokers and non-
smokers were found to have the same prevalence and titres of antibodies to E.coli and 
C. albicans, possibly because these infections are more associated with the gut than the 
respiratory tract (16).  At another level, smoking was reported to reduce the avidity but 
not the quantity of  IgG anti-human papillomavirus (HPV) antibodies generated in HPV 
vaccinated female subjects (46).  Thus, numerous direct and indirect effects of cigarette 
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smoking are likely to contribute to the changes in total Ig and specific antibody levels 
in smokers. 
 In addition to the qualitative effects of smoking on Ig class levels, the 
quantitative changes in Ig concentrations associated with smoking are an important 
consideration in relation to the possible functional consequences.  IgG constitutes most 
of the Ig in blood, with a concentration about four times higher than IgA and ten times 
higher than IgM.  Thus, the 25-30% reduction in serum IgG concentrations associated 
with smoking observed in the present study could be particularly biologically 
significant.  Similarly, the reduced levels of IgG and IgM in the saliva of smokers could 
be significant despite the slight rise in salivary IgA, even though IgA has the highest 
concentrations in saliva.  The concentrations of IgD in both serum and saliva are too 
low to affect the overall Ig concentrations significantly. 
 Overall, the reduction in Ig levels associated with smoking might reasonably be 
considered as a form of moderate secondary immunodeficiency (47, 48).  Similarly, the 
associations between smoking and autoimmune diseases (5) might result from smoking 
inducing a degree of immunodeficiency (including reduced Ig levels) that causes 
inadequate control of infective agents which, in turn, promote the development of 
autoimmunity (3, 49).  This model provides a plausible link between smoking and 
infections as two environmental factors both known to be associated with autoimmune 
diseases (5, 49). 
 In addition to its association with autoimmune diseases, cigarette smoke is the 
main risk factor for COPD (4).  In this context, others have shown that about 25% of 
COPD patients have total serum IgG levels below the lower limit of normal (50), 
consistent with our findings in smokers without COPD. This is associated with an 
increased incidence of exacerbations and hospitalizations (usually because of 
respiratory tract infections) and this is mainly in patients with deficiencies in IgG1 
and/or IgG2 subclasses (37).  This is consistent with reports that intra-venous Ig (IVIG) 
replacement therapy reduces respiratory infections and exacerbations in COPD (51, 
52).  Administration of IVIG is also beneficial in a range of autoimmune diseases (53), 
and substantial evidence exists for the occurrence of autoimmunity in COPD – 
particularly the production of autoantibodies (54, 55); thus, IVIG may help to reduce 
inflammation as well as infection in COPD.  
 To conclude, our data show reduced levels of IgG, and raised levels of IgA, in 
both the serum and saliva of smokers compared to never-smokers. By contrast, IgM 
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and IgD levels were differentially affected in serum and saliva by smoking.  The clear 
evidence for reduced IgG levels associated with smoking in this and other studies may 
relate to the link between smoking and both autoimmune diseases and COPD.  
 
Supporting Information 
Additional supporting information may be found online in the Supporting Information 
section at the end of the article.  
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Table 1.  The effect of cigarette smoking on immunoglobulin levels in serum. 
 
Study [ref] Date Method IgG IgA IgM IgD 
Tarbiah et al [this paper] 2018 Microarray v ^ ^ v 
Calapai et al [15] 2009 ELISA v – –  
Andersen et al [16] 1982 Immunodiffusion v v –  
McMillan et al [17] 1997 Nephelometry v – –  
Gonzalez-Q. et al [18] 2008 Nephelometry v – –  
Prajapati et al [19] 2016 Nephelometry ^ ^   
Bahna et al [20] 1983 RIA    ^ 
Al-Ghamdi et al [21] 2007 Turbidimetry v v –  
Carballo et al [22] 2017 Turbidimetry    ^ 
Total relevant studies   7 7 6 3 
Increased by smoking   1 2 1 2 
No effect of smoking   0 3 5 0 
Decreased by smoking   6 2 0 1 
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Table2.  The effect of cigarette smoking on immunoglobulin levels in saliva. 
 
Study Date Method IgG IgA IgM IgD 
Tarbiah et al [this paper] 2018 Microarray v ^ v – 
Barton et al [23] 1990 ELISA  v ^  
Norhagen E. et al [24] 1998 ELISA  ^   
Lie et al [25] 2002 ELISA  –   
Olayanju et al [26] 2012 ELISA – – v  
Golpasand Hagh [27] 2013 ELISA  v   
Giuca et al [28] 2014 ELISA v v v  
Nakonieczna-R. et al [29] 2016 ELISA  –   
Bennet et al [30] 1982 Immunodiffusion  v   
Doni et al [31] 2013 Immunodiffusion  v   
Koss et al [32] 2016 Immunodiffusion  –   
Shilpashree et al [33] 2012 Turbidimetry  v   
Total relevant studies   3 12 4 1 
Increased by smoking   0 2 1 0 
No effect of smoking   1 4 0 1 
Decreased by smoking   2 6 3 0 
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FIGURE LEGENDS 
 
Fig. 1.  Investigation by ELISA of cross-reactivity between anti-Ig capture and 
detection antibodies of different Ig class specificities with Ig standards of different 
classes. (a) IgG standard curves with high specificity; the capture and detection 
antibodies measured only IgG, but not IgM, IgA, or IgD. (b) IgM standard curves with 
high specificity; the capture and detection antibodies measured only IgM, but not IgG, 
IgA, or IgD. (c) IgA standard curves with high specificity; the capture and detection 
antibodies measured only IgA, but not IgG, IgM, or IgD. (d) IgD standard curves with 
high specificity; the capture and detection antibodies measured only IgD, but not IgG, 
IgM, or IgA. 
 
 
 
Fig. 2.  Investigation by microarray of cross-reactivity between IgM, IgA and IgD 
standards with anti-IgG.  Anti-human IgG was used as the capture antibody, and an HRP-
conjugated goat anti-human IgG-Fc antibody served as the detection antibody. No cross-
reactivity was observed between the IgM, IgA or IgD standards with an anti-human IgG 
capture antibody and an HRP-conjugated goat anti-human IgG antibody as the detection 
antibody. IgG standard curves were generated on three different occasions. The values 
for IgD were completely undetectable and therefore do not appear on this figure.  
 
 
 
Fig. 3.  Determination of a suitable serum dilutions. The interpolated samples with a 
dilution of 1:40,000 fit in the middle of the standard curves for IgG and IgA, and a 
1:200 dilution was used to measure IgM and IgD. 
 
 
Fig. 4.  Comparing the Ig concentrations in serum samples and saliva samples from 
smokers and non-smoker subjects using a Mann–Whitney test revealed significant 
differences. (a) Serum IgG concentrations were lower in smokers than in non-smoker 
subjects (p < 0.0001). (b) Seruem IgM concentrations were higher in smokers than in 
non-smoker subjects (P < 0.0001). (c) Serum IgA concentrations were higher in 
smokers than in non-smoker subjects (P < 0.05). (d) Serum IgD concentrations were 
lower in smokers than in non-smoker subjects (P < 0.05).  (e) Salivary IgG 
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concentrations were lower in smokers than in non-smokers (P < 0.05). (f) Salivary IgM 
concentrations were lower in smokers than in non-smokers (P < 0.0001). (g) Salivary 
IgA concentrations were higher in smokers than in non-smokers (P < 0.05). (h) Salivary 
IgD concentrations were not significantly different between smokers and non-smokers. 
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Figure 2. 
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Figure 4. 
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Abstract                                                                                    
The aim of the present study was to compare concentrations of IgG, IgA, IgM and IgD 
in both serum and saliva samples from smoking and non-smoking subjects using a 
protein microarray assay.  The findings were also compared to previous studies.  Serum 
and saliva were collected from 48 smoking male subjects and 48 age-matched never-
smoker male subjects.  The protein microarray assays for detection of human IgG, IgM, 
IgA and IgD were established and optimized using Ig class-specific affinity purified 
goat anti-human Ig-Fc capture antibodies and horseradish peroxidase (HRP)-
conjugated goat anti-human Ig-Fc detection antibodies.  The Ig class specificity of the 
microarray assays was verified and the optimal dilutions of serum and saliva samples 
was determined for quantification of Ig levels against standard curves.  We found that 
smoking is associated with reduced IgG concentrations and enhanced IgA 
concentrations in both serum and saliva.  By contrast, smoking differentially affected 
IgM concentrations – causing increased concentrations in serum, but decreased 
concentrations in saliva.  Smoking was associated with decreased IgD concentrations 
in serum, and did not have a significant effect on the very low IgD concentrations in 
saliva.  Thus, cigarette smoking differentially affects the levels of Ig classes 
systemically and in the oral mucosa.  Although there is variation between the results of 
different published studies, there is a consensus that smokers have significantly reduced 
levels of IgG in both serum and saliva.  A functional antibody deficiency associated 
with smoking may compromise the body’s response to infection and result in a 
predisposition to the development of autoimmunity.  
 
Keywords: cigarette smoke; immunoglobulin; IgG; IgA; IgM; IgD; serum; saliva; 
protein microarray. 
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Introduction 
Cigarette smoke (CS) has numerous toxic chemical constituents, which have cytotoxic, 
mutagenic, carcinogenic, and/or antigenic properties (1, 2).  The immune system is 
affected in a variety of ways by CS, ranging from immunosuppression and increased 
susceptibility to infection to promotion of inflammation and immunopathology (3).  
With regard to the latter, CS is the major cause of chronic obstructive pulmonary 
disease (COPD) (4), and smoking is a recognised risk factor for the occurrence of 
autoimmune diseases (5). 
 An important facet of these effects is that CS causes dysregulation and 
impairment of B lymphocytes (6-10); nicotinic receptors are expressed by B cells (11), 
and long-term exposure to nicotine can suppress B cell development, proliferation and 
immune functions (9, 12-14).  Numerous studies have investigated the effects of 
tobacco smoking on immunoglobulin (Ig) levels using a variety of assays.  In serum 
samples from smokers and non-smokers, Igs have been quantified by ELISA (15), 
immunodiffusion assay (16), nephelometry (17-19), radioimmunoassay (20) and 
turbidimetry (21, 22).  Investigations of Ig levels in the saliva of smokers and non-
smokers have been carried out using mainly ELISA (23-29), although immunodiffusion 
assays (30-32) or turbidimetry (33) have also been used.  These studies have generated 
varying results concerning the effects of smoking on the concentrations of different Ig 
classes (IgG, IgA, IgM) in serum or saliva, reporting that smoking is associated with 
increased, decreased or unchanged Ig class concentrations compared to non-smoking 
controls.  However, these studies have not investigated simultaneously the effects of 
smoking on Ig class concentrations in both serum and saliva in the same subjects.  In 
addition, few of these studies have investigated the effects of smoking on levels of IgD 
(20, 22): this is expressed particularly in the upper aerodigestive tract in humans (34), 
which is heavily exposed to CS in smokers. 
 The aim of the present study was therefore the compare concentrations of IgD, 
as well as IgG, IgA and IgM, in both serum and saliva samples from smoking and 
non-smoking subjects.  Furthermore, this was undertaken using a protein microarray 
assay to quantify the Ig class levels – this relatively recent technique was not used in 
any of the previous studies referred to above (15-33).  The protein microarray used 
was essentially a miniaturised version of a sandwich/capture ELISA.  However, in 
comparison to ELISAs, microarrays require smaller sample volumes, are more 
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sensitive and have a greater dynamic range. These factors make microarrays a cheaper 
and potentially more sensitive alternative to ELISAs for the large-scale detection of 
known proteins, including Igs (35). 
 
Materials and Methods 
The study was conducted in accordance with the Basic & Clinical Pharmacology & 
Toxicology policy for experimental and clinical studies (36). 
 
Subjects. Serum and saliva were collected from 48 smoking male subjects (median age 
= 30 years; age range 19-51) and 48 age-matched never-smoker male subjects (median 
age = 32.5 years; age range 20-56), all of whom were blood bank volunteers at King 
Abdulaziz Hospital, Jeddah, Saudi Arabia.  As healthy blood bank volunteer donors at 
the time of sample collection, all the subjects fulfilled the following criteria:   No history 
or evidence of significant illness/disease, including lung/respiratory tract, heart/chest, 
liver, kidney, nervous system, diabetes, cancer.  No infectious diseases or recent 
vaccinations, fever, flu-like illness, sore throat or antibiotic treatment.  No recent dental 
extractions.  No recent surgery, blood transfusion or organ transplantation.  No recent 
anaemia, high blood pressure or abnormal pulse.  
 The serum and saliva samples were aliquoted and stored at -20oC. They were 
transported on ice to Queen’s Medical Centre, Nottingham, UK, and then stored frozen 
until assayed. Ethical approval was granted by The Biomedical Research Ethics 
Committee, Ministry of Higher Education, King Abdulaziz University, Faculty of 
Medicine.  The smoking subjects smoked a median of 20 cigarettes/day (range 1-40), 
and had smoked for a median of 10 years (range 2-33). 
 Donors ceased from eating and drinking (and smoking) about 1 hour prior to 
donation. Smoker and non-smoker donors were requested to provide 10 ml of blood 
and 5 ml of unstimulated saliva after signing an informed-consent form. Blood samples 
were collected in plain serum separation tubes (BD Vacutainer™ Venous Blood 
Collection Tubes: SST™ Serum Separation Tubes: Hemogard). The tubes were 
centrifuged at 2000g for 10 minutes. Saliva was collected over a period of 5-10 minutes. 
After cleaning the mouth with mouthwash and rinsing with water over 5 min, donors 
provided saliva into plain separation tubes (Thermo Fisher Scientific) and the tubes 
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kept on ice. Then, the saliva samples were centrifuged at 2600g for 15 minutes at 4°C. 
Samples were aliquoted and immediately frozen at −20°C.  
 
Human Ig class microarrays. Affinity purified goat anti-human Ig-Fc capture 
antibodies and horseradish peroxidase (HRP)-conjugated goat anti-human Ig-Fc 
detection antibodies provided in the Bethyl Laboratories Human IgG/IgA/IgM/IgD 
ELISA Quantitation Sets (obtained from Cambridge Bioscience) were used to 
established the microarray assay for quantifying human IgG, IgA, IgM and IgD, 
respectively. As accurate quantification of each Ig class requires the capture and 
detection antibodies to be highly specific for the relevant class, this was initially 
confirmed by running the Ig class-specific ELISAs according to the manufacturer’s 
instructions and demonstrating that each capture/detection antibody pair bound only the 
relevant class of purified Ig (obtained from Athenas Research Technology); for 
example, the anti-IgG-Fc capture and detection antibodies detected human IgG, but not 
IgA, IgM or IgD (Figure 1).   
 To transpose the assay to the microarray platform, optimisation studies were 
undertaken to determine the optimal printing buffer, blocking buffer, and 
concentrations of each capture antibody and detection antibody.  The optimised 
microarray assays for detection of human IgG, IgA, IgM and IgD were then performed 
as follows: 
 Capture antibody goat anti-human Ig-Fc (100μg/ml in PBS-Trehalose 
(50mM)) was loaded onto a 384 well plate (Genetix), and printed in double 
quadriplicate in a 16 x16 array format onto a poly-l-lysine-coated glass slide 
(Thermofisher, UK) using a Biorobotics Microgrid II arrayer (Microgrid) and a 
silicon contact pin (Parallel Synthesis Technologies, USA). During printing, the array 
chamber was set to 200C and 60% humidity, and the spot diameter was 315μm. Slides 
were held under a vacuum overnight. On the next day, the slides were blocked with 
BSA blocking buffer with shaking for 1 h at room temperature. After incubation, the 
slides were washed 3 times with PBS containing 0.05 % Tween-20 on the shaker for 3 
min each wash. Ig standards, serum and saliva samples were added and incubated for 
1 h. Following incubation, the slides were washed as described above. Then, 100 l of 
the HRP-conjugated detection antibody was added and the slides were incubated for 1 
h at room temperature on a shaker.  The slides were washed, as described above, and 
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100 l biotinylated-tyramide amplification reagent was applied to the slides and 
incubated for 10 min at room temperature. After the incubation, the slides were 
washed as described above, and 100 l Cy5-conjugated streptavidin (1:1000 in 3 % 
BSA) was applied to each block. The slides were incubated for 15 min on the shaker 
in the dark. Finally, the slides were released from the holder, washed in ultra-pure 
water for 5 min, and centrifuged for 3 min. After processing, slides were immediately 
scanned in a GenePix 4200AL microarray scanner, to measure the fluorescence (Cy5 
Fluor 635).  
 The microarray assays had intra-assay coefficient of variation (CV) <10%, and 
inter-assay CV <15%.  The Ig class specificity demonstrated in the ELISA format was 
maintained in the microarray assays, as exemplified for detection of IgG (Figure 2). 
 
Statistical Analysis.  The data were not normally distributed and therefore comparisons 
between groups were made using the Kruskal-Wallis test for non-paired data. Statistical 
analyses were performed using GraphPad Prism 7. 
 
Results 
Determining optimal sample dilutions for Ig class quantification. 
The microarray assays for detection of human IgG, IgM, IgA and IgD were established 
and optimized as described in the Material & Methods section.  Experiments were 
undertaken to determine the optimal dilutions of human serum for accurate 
quantification of each Ig class.  As shown in figure 3, the serum dilutions that generated 
signals corresponding to the sensitive regions of the standard curves were 1:40,000 for 
IgG and IgA, and 1:200 for IgM and IgD.  A saliva dilution of 1:2 was suitable for 
detection of salivary Igs (data not shown). 
 
Serum Ig class concentrations in smokers and non-smokers. 
The serum Ig concentrations for the smokers and non-smokers are shown in figure 4a-
d.  The IgG levels in smokers were very significantly lower than those in non-smokers 
(p<0.0001; figure 4a); conversely, the serum IgM levels were very significantly higher 
in smokers than non-smokers (p<0.0001; figure 4b).   The serum IgA levels were also 
significantly higher in smokers (p<0.05; figure 4c), but the smokers’ IgD 
concentrations were significantly lower than in the non-smokers (p<0.05; figure 4d). 
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Salivary Ig class concentrations in smokers and non-smokers. 
Figure 4e-h shows that, as in serum, IgG concentrations in the saliva of smokers were 
significantly lower than in non-smokers (p<0.05; figure 4e), and salivary IgA 
concentrations were significantly higher in smokers (p<0.05; figure 4g).  By contrast, 
IgM levels were very significantly lower in the saliva of the smokers compared to the 
non-smokers (p<0.0001, figure 4f), which is the opposite of the findings for the serum 
levels of IgM described above (figure 4b).  There was no significant difference in the 
very low concentrations of salivary IgD between smokers and non-smokers (figure 4h). 
 There were no statistically significant correlations between serum and salivary 
Ig levels in the same subjects (either smokers or non-smokers) for any of the four Ig 
classes measured (data not shown). Also, there were no significant correlations between 
smoking pack-years and Ig class levels in either serum or saliva samples. 
 
 
Discussion 
Our findings indicate that smoking is associated with reduced IgG concentrations in 
both serum and saliva, and enhanced IgA concentrations in both serum and saliva.  By 
contrast, smoking differentially affected IgM concentrations – causing increased 
concentrations in serum, but decreased concentrations in saliva.  We found smoking to 
be associated with decreased IgD concentrations in serum, and not to have a significant 
effect on the very low IgD concentrations in saliva. 
 Tables 1 and 2 summarize the findings in the present study, together with the 
results reported in previous studies (quoted in the Introduction) that investigated the 
effects of smoking on levels of IgG, IgM, IgA and IgD in serum (Table 1) or in saliva 
(Table 2).  As mentioned in the Introduction, unlike the present study, these previous 
studies did not investigate Ig concentrations in both serum and saliva; few determined 
IgD concentrations (two for serum and none for saliva); and none used microarray 
technology.  The advantages of the microarray platform include its sensitivity and broad 
dynamic range (0 to 65,000 fluorescence units, compared to the 0 to 4 optical density 
units in ELISA), and the increased number of replicates that can readily be performed 
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within an assay together with detailed feature analysis enabling poorly-performing 
replicates to be legitimately excluded, hence reducing replicate variation. 
 Considering all the studies summarized in Tables 1 and 2 that investigated the 
effects of smoking on IgG levels, 6/7 (including the present study) reported a significant 
decrease in IgG concentrations in the serum of smokers; also 2/3 studies (including the 
present study) reported a significant reduction in IgG levels in the saliva of smokers. 
Thus, there is a strong consensus of evidence that smoking is associated with reduced 
IgG levels both systemically and in the oral mucosa.  It would be of interest to examine 
the effects of smoking on IgG subclasses, especially as these are known to be affected 
in COPD (37). 
 By contrast, there is no clear consensus for the effects of smoking on IgA levels, 
with different studies reporting an increase, a decrease, or no effect of smoking on IgA 
concentrations in either serum (Table 1) or saliva (Table 2).  The reason for this 
variation are unclear:  it does not appear to be related to different types of assays being 
used (e.g. nephelometry versus turbidimetry versus ELISA, etc.) since, for example, 
amongst the seven studies that used ELISA to determine salivary IgA levels, one 
reported an increase, three reported no change and three reported a decrease in smokers 
compared to non-smokers.  Other possible factors leading to the variations could 
include ethnicity, amount of smoking and relative detection of IgA1 versus IgA2. 
 Five studies listed in Table 1 reported no significant effects of smoking on 
serum levels of IgM, whereas a very significant increase in smokers was observed in 
the present study.  This may be because, in the present study, several smokers had 
particularly high serum IgM concentrations, plus very little variation was found in the 
serum IgM levels of non-smokers (figure 4b).  On the other hand, the present study 
agrees with 2/3 other studies in finding reduced levels of IgM in the saliva of smokers 
compared to non-smokers.  Overall, the present study agrees with the consensus view 
of other studies that smoking has different effects on IgM levels in serum and saliva. 
 The concentrations of IgD are very low in serum and extremely low in saliva, 
with an insufficient number of studies for a consensus view on the effects of smoking 
to be drawn.  There is, therefore, clear scope for further studies of the effects of smoking 
on IgD levels in both serum and saliva.  The importance of IgD in the upper 
aerodigestive tract in humans is indicated by the high numbers of IgD-producing B cells 
in tonsils, adenoids, salivary and lachrymal glands, and nasal mucosa; whereas IgD 
producing B cells are much less frequent in peripheral lymph nodes, spleen, bone 
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marrow and intestinal mucosa (34).  Furthermore, IgD recognizes a range of pathogenic 
microbes often found in the upper aerodigestive tract of humans, consistent with a 
protective role for IgD in this location (34).  A better understanding of the effects of 
smoking on IgD is therefore important. 
 Although the effects of tobacco smoking on IgE levels were not the subject of 
the present study, this is clearly of importance, not least since smoking exacerbates 
allergic conditions.  Numerous previous studies have shown that tobacco smoking is 
associated with elevated levels of serum IgE (38-43); it would also be of interest to 
determine the effects of smoking on salivary IgE. 
 The lack of correlation between smoking pack years and Ig class levels in serum 
and saliva that we observed is broadly consistent with the findings of others.  One study 
reported a significant inverse correlation between salivary IgA concentrations and 
current level of smoking, but no correlation between smoking and salivary IgG or IgM 
concentrations (23).  By contrast, another study reported there to be no correlation 
between salivary IgA levels and frequency of duration of smoking (33).  With regard 
to serum Igs, no significant correlation was found between IgD levels and duration of 
smoking (20).  Another study reported a significant correlation between serum IgG 
concentrations and the number of cigarettes smoked per day; however, these authors 
also pointed out that there was a clearly significant difference in serum IgG levels 
between  non-smokers and those a relatively low number of cigarettes (≤10 per day) 
(17).  They also reported a low significance for the correlation between IgM 
concentrations and level of smoking, but no significance for the correlation of IgA 
levels and smoking (17).  Overall, our findings, and these previous studies, are 
consistent with the proposal that any level of cigarette smoking affects Ig levels in 
serum and saliva, with smoking per se being the main factor, regardless of whether the 
level of smoking is low, moderate or high.   
 A variety of mechanisms could be involved in the differential effects of smoking 
on the concentrations of Ig classes in serum and saliva:  these might include direct 
effects on B cells and indirect effects on T cells and antigen presenting cells, which 
could affect Ig class switching and/or differential survival of naïve B cells or memory 
B cells (3).  In this regard, we have preliminary evidence (see online Supporting 
Information) that the in vitro production of IgG, IgM and IgA by human peripheral 
blood mononuclear cells (PBMCs) or purified B cells stimulated with anti-CD40 plus 
IL-4 and pokeweed mitogen is inhibited by cigarette smoke extract or nicotine.  It is 
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interesting that pure nicotine appears to suppress Ig production to the same extent as 
CSE, suggesting that nicotine is an important contributor to the Ig-suppressive effect of 
whole CSE.  Furthermore, these observations are consistent with the investigations of 
Skok et al. in murine models into the effects of nicotinic acetylcholine receptors 
(nAChRs) expressed by immature and mature B cells (12-14).  They deduced that the 
activity of nAChR promotes the survival and development of immature B cells in the 
bone marrow, but suppresses B cell activation in response to antigenic challenge in 
secondary lymphoid tissues like the spleen (12, 13).  In this regard, wild-type mice 
(expressing nAChR) were found to produce higher levels of natural antibodies that 
nAChR-knockout mice, but wild-type mice produced lower levels of antigen-specific 
IgG antibodies than the nAChR-knockout mice when challenged (12).  This may help 
to explain our observation that smokers, compared to non-smokers, have very 
significantly lower levels of serum IgG (most of which is derived from antigen-
stimulated B cells), but very significantly higher levels of serum IgM (that may include 
a higher proportion of natural antibodies).  By contrast, different processes are likely to 
determine salivary Ig, where we found both IgG and IgM to be decreased in smokers.  
 It should also be noted, however, that the suppression by CSE and nicotine of 
IgA and IgM production by polyclonally-stimulated PBMCs and B cells (see online 
Supporting Information)  is in contrast to our findings that IgA levels were increased in 
the sera and saliva of smokers, as were the levels of IgM in smokers’ sera.  This suggests 
that the in vitro findings cannot fully explain the effects of CSE and nicotine in smokers 
in vivo, which are likely to be much more complex.  For example, the increased 
occurrence of infections in the upper respiratory tract of smokers (44) is likely to 
stimulate the production of IgA as a major mucosal Ig.  This complexity is also reflected 
in the effects of cigarette smoking on antibodies specific to particular antigens, as 
distinct from total Ig class levels.  For example, smokers were reported to have raised 
levels of anti-pneumococcal IgG antibodies, presumably due to an increased occurrence 
of pneumococcal infections of the respiratory tract (45).  By contrast, smokers and non-
smokers were found to have the same prevalence and titres of antibodies to E.coli and 
C. albicans, possibly because these infections are more associated with the gut than the 
respiratory tract (16).  At another level, smoking was reported to reduce the avidity but 
not the quantity of  IgG anti-human papillomavirus (HPV) antibodies generated in HPV 
vaccinated female subjects (46).  Thus, numerous direct and indirect effects of cigarette 
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smoking are likely to contribute to the changes in total Ig and specific antibody levels 
in smokers. 
 In addition to the qualitative effects of smoking on Ig class levels, the 
quantitative changes in Ig concentrations associated with smoking are an important 
consideration in relation to the possible functional consequences.  IgG constitutes most 
of the Ig in blood, with a concentration about four times higher than IgA and ten times 
higher than IgM.  Thus, the 25-30% reduction in serum IgG concentrations associated 
with smoking observed in the present study could be particularly biologically 
significant.  Similarly, the reduced levels of IgG and IgM in the saliva of smokers could 
be significant despite the slight rise in salivary IgA, even though IgA has the highest 
concentrations in saliva.  The concentrations of IgD in both serum and saliva are too 
low to affect the overall Ig concentrations significantly. 
 Overall, the reduction in Ig levels associated with smoking might reasonably be 
considered as a form of moderate secondary immunodeficiency (47, 48).  Similarly, the 
associations between smoking and autoimmune diseases (5) might result from smoking 
inducing a degree of immunodeficiency (including reduced Ig levels) that causes 
inadequate control of infective agents which, in turn, promote the development of 
autoimmunity (3, 49).  This model provides a plausible link between smoking and 
infections as two environmental factors both known to be associated with autoimmune 
diseases (5, 49). 
 In addition to its association with autoimmune diseases, cigarette smoke is the 
main risk factor for COPD (4).  In this context, others have shown that about 25% of 
COPD patients have total serum IgG levels below the lower limit of normal (50), 
consistent with our findings in smokers without COPD. This is associated with an 
increased incidence of exacerbations and hospitalizations (usually because of 
respiratory tract infections) and this is mainly in patients with deficiencies in IgG1 
and/or IgG2 subclasses (37).  This is consistent with reports that intra-venous Ig (IVIG) 
replacement therapy reduces respiratory infections and exacerbations in COPD (51, 
52).  Administration of IVIG is also beneficial in a range of autoimmune diseases (53), 
and substantial evidence exists for the occurrence of autoimmunity in COPD – 
particularly the production of autoantibodies (54, 55); thus, IVIG may help to reduce 
inflammation as well as infection in COPD.  
 To conclude, our data show reduced levels of IgG, and raised levels of IgA, in 
both the serum and saliva of smokers compared to never-smokers. By contrast, IgM 
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and IgD levels were differentially affected in serum and saliva by smoking.  The clear 
evidence for reduced IgG levels associated with smoking in this and other studies may 
relate to the link between smoking and both autoimmune diseases and COPD.  
 
Supporting Information 
Additional supporting information may be found online in the Supporting Information 
section at the end of the article.  
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Table 1.  The effect of cigarette smoking on immunoglobulin levels in serum. 
 
Study [ref] Date Method IgG IgA IgM IgD 
Tarbiah et al [this paper] 2018 Microarray v ^ ^ v 
Calapai et al [15] 2009 ELISA v – –  
Andersen et al [16] 1982 Immunodiffusion v v –  
McMillan et al [17] 1997 Nephelometry v – –  
Gonzalez-Q. et al [18] 2008 Nephelometry v – –  
Prajapati et al [19] 2016 Nephelometry ^ ^   
Bahna et al [20] 1983 RIA    ^ 
Al-Ghamdi et al [21] 2007 Turbidimetry v v –  
Carballo et al [22] 2017 Turbidimetry    ^ 
Total relevant studies   7 7 6 3 
Increased by smoking   1 2 1 2 
No effect of smoking   0 3 5 0 
Decreased by smoking   6 2 0 1 
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Table2.  The effect of cigarette smoking on immunoglobulin levels in saliva. 
 
Study Date Method IgG IgA IgM IgD 
Tarbiah et al [this paper] 2018 Microarray v ^ v – 
Barton et al [23] 1990 ELISA  v ^  
Norhagen E. et al [24] 1998 ELISA  ^   
Lie et al [25] 2002 ELISA  –   
Olayanju et al [26] 2012 ELISA – – v  
Golpasand Hagh [27] 2013 ELISA  v   
Giuca et al [28] 2014 ELISA v v v  
Nakonieczna-R. et al [29] 2016 ELISA  –   
Bennet et al [30] 1982 Immunodiffusion  v   
Doni et al [31] 2013 Immunodiffusion  v   
Koss et al [32] 2016 Immunodiffusion  –   
Shilpashree et al [33] 2012 Turbidimetry  v   
Total relevant studies   3 12 4 1 
Increased by smoking   0 2 1 0 
No effect of smoking   1 4 0 1 
Decreased by smoking   2 6 3 0 
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FIGURE LEGENDS 
 
Fig. 1.  Investigation by ELISA of cross-reactivity between anti-Ig capture and 
detection antibodies of different Ig class specificities with Ig standards of different 
classes. (a) IgG standard curves with high specificity; the capture and detection 
antibodies measured only IgG, but not IgM, IgA, or IgD. (b) IgM standard curves with 
high specificity; the capture and detection antibodies measured only IgM, but not IgG, 
IgA, or IgD. (c) IgA standard curves with high specificity; the capture and detection 
antibodies measured only IgA, but not IgG, IgM, or IgD. (d) IgD standard curves with 
high specificity; the capture and detection antibodies measured only IgD, but not IgG, 
IgM, or IgA. 
 
 
 
Fig. 2.  Investigation by microarray of cross-reactivity between IgM, IgA and IgD 
standards with anti-IgG.  Anti-human IgG was used as the capture antibody, and an HRP-
conjugated goat anti-human IgG-Fc antibody served as the detection antibody. No cross-
reactivity was observed between the IgM, IgA or IgD standards with an anti-human IgG 
capture antibody and an HRP-conjugated goat anti-human IgG antibody as the detection 
antibody. IgG standard curves were generated on three different occasions. The values 
for IgD were completely undetectable and therefore do not appear on this figure.  
 
 
 
Fig. 3.  Determination of a suitable serum dilutions. The interpolated samples with a 
dilution of 1:40,000 fit in the middle of the standard curves for IgG and IgA, and a 
1:200 dilution was used to measure IgM and IgD. 
 
 
Fig. 4.  Comparing the Ig concentrations in serum samples and saliva samples from 
smokers and non-smoker subjects using a Mann–Whitney test revealed significant 
differences. (a) Serum IgG concentrations were lower in smokers than in non-smoker 
subjects (p < 0.0001). (b) Seruem IgM concentrations were higher in smokers than in 
non-smoker subjects (P < 0.0001). (c) Serum IgA concentrations were higher in 
smokers than in non-smoker subjects (P < 0.05). (d) Serum IgD concentrations were 
lower in smokers than in non-smoker subjects (P < 0.05).  (e) Salivary IgG 
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concentrations were lower in smokers than in non-smokers (P < 0.05). (f) Salivary IgM 
concentrations were lower in smokers than in non-smokers (P < 0.0001). (g) Salivary 
IgA concentrations were higher in smokers than in non-smokers (P < 0.05). (h) Salivary 
IgD concentrations were not significantly different between smokers and non-smokers. 
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Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Thank you very much for considering this manuscript for publication in Basic and Clinical 
Pharmacology and Toxicology.  We are very pleased that the manuscript is deemed 
acceptable, subject to an appropriate response to the reviewers’ comments. 
 
We are very grateful to the reviewers for their careful reading of the manuscript and for 
their helpful and constructive comments.  Our responses to these comments are as follows: 
 
Reviewer 1: 
 
This comment in the discussion: "Thus, the 25-30% reduction in serum IgG concentrations 
associated with smoking observed in the present study would not be fully 'compensated' by 
the increase in serum IgA and IgM concentrations observed in smokers. "  I believe should 
be omitted since different classes of Igs serve different functions and have different 
distributions, they cannot really compensate each other. 
Response: Thank you for drawing attention to this – we agree that this statement is 
misleading. We have therefore modified the sentence to read as follows: “Thus, the 25-30% 
reduction in serum IgG concentrations associated with smoking observed in the present 
study could be particularly biologically significant.” 
 
This other comment; "Overall, the reduction in Ig levels associated with smoking might 
reasonably be considered as a form of hypogammaglobulinaemia which, in the context of 
primary antibody deficiencies (e.g. common variable immunodeficiency), is known to be 
associated with autoimmune disorders (44, 45)." I would suggest, "Overall, the reduction in 
Ig levels associated with smoking might reasonably be considered as a form of moderate 
secondary immunodeficiency (44, 45)."  This is because common variable immunodeficiency 
is a primary immunodeficiency and goes with more markedly reduction of Igs levels and 
requires the demonstration of a functional impairment of specific antibody response. 
Secondary immunodeficiencies do not associate with autoimmunity (or nor clearly). 
Response:  We agree with this helpful comment and have changed the sentence as 
proposed. 
 
 
Reviewer 2: 
 
This is an interesting paper that falls within the scope of the journal. 
It covers describes the development of a novel assay for measuring Ig 
concentrations, and the application of the assay to compare the levels different 
Ig classes in serum and saliva of smokers and non-smokers.  The paper also 
includes supplemental data on the effects of smoke extract and nicotine on Ig 
secretion in vitro and a review of previously published data. 
The work is clearly presented and well-described, and the data make a worthwhile 
contribution to the important field of the effects of smoking on immunity.  The 
main part of the study, measuring Ig, is well-designed and appropriate conclusions 
are drawn.  The inclusion of preliminary results on Ig production in vitro is also 
helpful, and although it would have strengthened the conclusions had more samples 
been tested, the work is appropriate for supplemental data. 
Response: Thank you for these positive and supportive comments. 
 
There are discussion points that could be addressed or amplified.  The question of 
the correlation (or lack) between Ig levels for heavy and light smoking merits 
more consideration….. 
Response: Thank you for drawing attention to this important point.  We have added the 
following paragraph to the discussion to address this: “The lack of correlation between 
smoking pack years and Ig class levels in serum and saliva that we observed is broadly 
consistent with the findings of others.  One study reported a significant inverse correlation 
between salivary IgA concentrations and current level of smoking, but no correlation 
between smoking and salivary IgG or IgM concentrations (23).  By contrast, another study 
reported there to be no correlation between salivary IgA levels and frequency of duration of 
smoking (33).  With regard to serum Igs, no significant correlation was found between IgD 
levels and duration of smoking (20).  Another study reported a significant correlation 
between serum IgG concentrations and the number of cigarettes smoked per day; however, 
these authors also pointed out that there was a clearly significant difference in serum IgG 
levels between  non-smokers and those a relatively low number of cigarettes (≤10 per day) 
(17).  They also reported a low significance for the correlation between IgM concentrations 
and level of smoking, but no significance for the correlation of IgA levels and smoking (17).  
Overall, our findings, and these previous studies, are consistent with the proposal that any 
level of cigarette smoking affects Ig levels in serum and saliva, with smoking per se being the 
main factor, regardless of whether the level of smoking is low, moderate or high.” 
 
….. as does the observation that smokers have higher IgA levels in 
serum and saliva, whilst smoke extract/nicotine suppresses IgA production in 
vitro.  More detailed consideration as to whether specific antibody responses 
might be reflected by the differences in Ig class would be helpful. 
Response: These are also both very good points, thank you.  We have added the following 
paragraph to the Discussion that is intended to address these points: “It should also be 
noted, however, that the suppression by CSE and nicotine of IgA and IgM production by 
polyclonally-stimulated PBMCs and B cells (see online Supporting Information)  is in contrast 
to our findings that IgA levels were increased in the sera and saliva of smokers, as were the 
levels of IgM in smokers’ sera.  This suggests that the in vitro findings cannot fully explain 
the effects of CSE and nicotine in smokers in vivo, which are likely to be much more 
complex.  For example, the increased occurrence of infections in the upper respiratory tract 
of smokers (44) is likely to stimulate the production of IgA as a major mucosal Ig.  This 
complexity is also reflected in the effects of cigarette smoking on antibodies specific to 
particular antigens, as distinct from total Ig class levels.  For example, smokers were 
reported to have raised levels of anti-pneumococcal IgG antibodies, presumably due to an 
increased occurrence of pneumococcal infections of the respiratory tract (45).  By contrast, 
smokers and non-smokers were found to have the same prevalence and titres of antibodies 
to E.coli and C. albicans, possibly because these infections are more associated with the gut 
than the respiratory tract (16).  At another level, smoking was reported to reduce the avidity 
but not the quantity of  IgG anti-human papillomavirus (HPV) antibodies generated in HPV 
vaccinated female subjects (46).  Thus, numerous direct and indirect effects of cigarette 
smoking are likely to contribute to the changes in total Ig and specific antibody levels in 
smokers.” 
 
We hope that, with these modifications, the manuscript will now be fully acceptable for 
publication in Basic and Clinical Pharmacology and Toxicology. 
 
Yours faithfully, 
Lucy Fairclough 
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Tarbiah et al. – Supplementary Information. 
 
Cigarette smoking differentially affects immunoglobulin class levels in 
serum and saliva: an investigation and review. 
 
Isolation of PBMCs  
Buffy coats were obtained from anonymous blood donations via the Regional Blood 
Transfusion Service (Sheffield, UK), who provided ethical approval, within 24h of collection. 
Peripheral blood mononuclear cells (PBMCs) were isolated from 50ml buffy coat samples 
diluted into 150ml PBS. The diluted blood samples were transferred into 6 sterile 50ml 
centrifuge tubes each containing 10–15 ml Histopaque (Histopaque-1077; Sigma-Aldrich, 
Irvine, UK) and at 800g for 30 min. The white blood cell layer was collected with a sterile 
Pasteur pipette and placed into new sterile tubes, and 25 ml Hank’s Balanced Salt Solution 
was used to wash the cells (Hanks 123K2368; Sigma-Aldrich, Irvine, UK). The samples were 
centrifuged again at 800g for 10 min, and the supernatant was discarded. Then, the samples 
were washed twice in PBS with centrifugation at 300g for 10 min, after which they were 
counted.  
Magnetic separation of B cells  
To separate B cells, isolated PBMCs were subjected to immunomagnetic negative selection 
of B-lymphocytes, using a Negative B Cell Isolation Kit (Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany; Catalogue No. 130-091-151). Briefly, the cell pellet from the previous 
step was resuspended in cold MACS buffer (50ml PBS, 200µl EDTA, and 830µl of 30 % 
BSA; Sigma-Aldrich, Irvine, UK) at a ratio of 40µl/107 cells. Then, Biotin-Antibody 
Cocktail (cocktail of biotin-conjugated monoclonal antibodies against CD2, CD14, CD16, 
CD36, CD43, and CD235a) was added at a ratio of 10µl/107 total cells. Next, the samples 
were incubated for 5 min in a refrigerator (2–8oC). Subsequently, 30µl MACS buffer and 
20µl anti-Biotin Micro Beads were added/107 total cells, and the suspension was incubated 
for an additional 10 min in the refrigerator (2–8oC). Then, the cell suspension was 
resuspended in 1 ml MACS buffer and loaded onto a cold LS separation column (Catalogue 
No. 120-000-472; Miltenyi Biotec). Magnetic cell sorting was initiated after setting the 
magnet on the holder and the column on the cold magnet. A 3 ml LS column was equilibrated 
	 2	
with MACS buffer, and the cells were then passed through the column. The column was 
rinsed 3 times with 3 ml LS column MACS buffer to elute the B cells. After the third wash, 
the column was removed from the magnet and placed in a new sterile tube, and 3 ml MACS 
buffer/LS column was added and plunged through to remove the remaining leukocytes. The 
B cell samples were then centrifuged at 300g for 5 min to remove the MACS buffer. Finally, 
the B cells were resuspended at a concentration of 106/ml in RPMI 1640 complete medium 
(Catalogue No. RNBB7148; Sigma-Aldrich, Irvine, UK) supplemented with 10 mM HEPES, 
100 IU/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine (Sigma-Aldrich, Irvine, 
UK), and 10 % fetal bovine serum (FBS). Normally, the B cell preparation was 95 % pure 
(CD19+), with less than 0.5 % CD3+ T cells and CD14+ monocytes.  
Treatment of cell cultures with CSE or nicotine  
Unfractionated PBMCs and purified B cells were suspended in complete RPMI 1640 medium 
and cultured in 24-well tissue culture plates (Costar, High Wycombe, UK). Two ml of cell 
suspension was added to each well (2 x 106 cells/well). Cells were stimulated with a mixture 
of IL-4 (100 U/ml), anti-CD40 mAb (1 mg/ ml), and pokeweed mitogen. Some wells were 
treated with a 3% concentration of CSE, prepared as described previously (1). Nicotine 
(N3876, Sigma-Aldrich, Irvine, UK) was added at final concentration of 75µg/ml to assess 
the effects of this important constituent of cigarettes on B cells, and some cells were 
incubated with an equal amount of complete medium alone as a negative control. Cultures 
were routinely maintained at 37oC in a 5% CO2 humidified atmosphere for up to 8 days. 
Then, the supernatants were harvested by centrifugation at 400g for 10 min at 4oC. Cell-free 
supernatants was stored at -20oC until aliquots were used for IgG, IgM, IgA, and IgD 
determinations.  
Determination of Ig concentrations in culture supernatants 
Cell-free supernatants from PBMC and B cell cultures were diluted 1:10 in sample diluent 
and used to measure the levels of IgG, IgM, IgA, and IgD by capture ELISA using Bethyl 
Laboratories Human IgG/IgA/IgM/IgD ELISA Quantitation Sets (obtained from Cambridge	
Bioscience). 
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Results 
As shown in Figures S1 and S2, when human PBMCs or purified B cells were stimulated 
with a combination of IL-4, anti-CD40 and pokeweed mitogen, there was a marked increase 
in production/secretion of IgG, IgM and IgA compared to unstimulated cells; IgD was 
undetectable (data not shown).  However, the addition of 3% CSE or 75µg/ml nicotine to the 
cultures at the same time as the stimulators suppressed the production/secretion of IgG, IgM 
and IgA to levels similar to those seen in the unstimulated cultures.  Statistical analysis was 
not performed due to the low number of independent experimental repeats (n=3 or n=2, 
respectively). 
 
 
Fig. S1. Stimulated human PBMCs were incubated for 8 days in the presence of anti-CD40, 
IL-4, PWM, 3% CSE, or 75µg/ml nicotine. IgG, IgM, and IgA were detected in the 
supernatants by ELISA. a) IgG levels were lower in samples treated with CSE or nicotine, 
compared with samples treated only with stimulators. b) IgM levels were lower in samples 
treated with CSE or nicotine, compared with samples treated only with stimulators. c) IgA 
levels were lower in samples treated with CSE or nicotine, compared with samples treated 
only with stimulators.  Data from three independent donors is shown. 
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Fig. S2. Purified human B cells were incubated for 8 days in the presence of anti-CD40, IL-4, 
PWM, 3% CSE, or 75µg/ml nicotine. IgG, IgM, and IgA were detected in the supernatants 
by ELISA. a) IgG levels were lower in samples treated with CSE or nicotine, compared with 
samples treated only with stimulators. b) IgM levels were lower in samples treated with CSE 
or nicotine, compared with samples treated only with stimulators. c) IgA levels were lower in 
samples treated with CSE or nicotine, compared with samples treated only with stimulators. 
Data from two independent donors is shown. 
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